CARS...Been doing some DD on this.
Concerned about the 90 day PE's missing clinical significance in light of strong trends and one year data strengthening.
Cash burn is very high with the multiple trials and additional ancillary non stroke trials i.e. Gvhd and other immunological disorders
OS and Float not too bad for a start up company
Do like FDA SPA and Fast track and other EU and Japan expeditious review status for unmet disease states
Like the 10's of Billions market they are pursuing for stroke, MI's and others
Not sure what the specific MOA for Multistem is? I know it inhibits inflammatory mediators in the spleen for subsequent inhibition to the brain as well as Brain site specific inhibition to the ischemic area of the brain.
I "LOVE" the potential for a 36 hour duration of treatment intervention over the SOC current 4 to 6 hour Thrombolytic treatment
Will there be an interim readout on the Stroke trials?
How long are these trials until full completion. Are they going to wait for the one year morbidity/Mortality data, or will that be post approval P4 - like data?
Is there a high likelihood of another cash raise/dilution and perhaps R/S? in your analysis and opinion
I like the resume's of Management and the Board
Would it be prudent to continue and watch for a more attractive pps entry? We are currently at the 80% of the 52 week high (2.22) low
Still have more DD to do. Always appreciate your views, analysis and opinion CARS...as well as the rest of this Board...PRO's and CON"s..Thank you in Advance.....PEARSBY
News 
Market Data 
Discover 
